hydrocortisone butyrate / Generic mfg. - LARVOL DELTA

Contact Allergy to Topical Corticosteroids in Atopic Dermatitis: The Importance of Allergen Selection and Formulation in Diagnostic Accuracy (ISAD-RAJKA 2025) - "Patch testing was performed using the Polish Baseline Series and extended allergens including hydrocortisone acetate (ointment), hydrocortisone butyrate (alcoholic solution), and clobetasol propionate...While sensitization to gentamicin was observed more frequently in the AD group, this difference did not reach statistical significance. Patients with AD are at increased risk of clinically relevant contact allergy to corticosteroids. The pharmaceutical form of the allergen plays a decisive role in test sensitivity, underscoring the need for expanded and formulation-appropriate corticosteroid markers in diagnostics."

Allergy • Atopic Dermatitis • Contact Dermatitis • Dermatitis • Dermatology • Immunology

A phase II study evaluating the preventive effect of topical hydrocortisone for capecitabine-induced hand-foot syndrome in patients with colorectal cancer receiving adjuvant chemotherapy with capecitabine plus oxaliplatin (T-CRACC study). (PubMed, Int J Clin Oncol) - "Topical hydrocortisone butyrate (0.1%) may prevent capecitabine-induced hand-foot syndrome."

Journal • P2 data • Colorectal Cancer • Dermatology • Hematological Disorders • Neutropenia • Oncology • Pain • Solid Tumor

Efficacy of Chi-Huang cream as an anti-inflammatory and anti-pruritic agent in treating chronic pruritus. (PubMed, Fitoterapia) - "The high-dose Chi-Huang (CH-H) group showed significantly improved skin lesions, reduced scratching behavior, and decreased skin thickness compared to the saline group, with efficacy comparable to hydrocortisone butyrate (HBC)...In a conclusion, Chi-Huang cream exhibits significant anti-inflammatory and anti-pruritic effects under a SADBE-induced ACD condition, with minimal impact on spleen and thymus indices. These findings suggest Chi-Huang cream may serve as a promising therapeutic agent in treating chronic pruritus."

Journal • Atopic Dermatitis • Contact Dermatitis • Dermatitis • Dermatology • Immunology • Pruritus

A Case of Idiopathic Follicular Mucinosis Treated Successfully with Cyclosporine. (PubMed, Acta Dermatovenerol Croat) - "Treatment includes local or systemic corticosteroids, dapsone, indomethacin, interferon, hydroxychloroquine, and minocycline; however, some patients do not respond to these treatments (2)...Oral roxithromycin, topical hydrocortisone butyrate ointment, and oral indomethacin did not ameliorate the plaque...It has been also reported that topical pimecrolimus was effective (4) and that most lymphocytes infiltrating the perifollicular area in patients with FM were CD4-positive T-cells (3), which suggests that cyclosporine was efficacious because it suppressed T-cell production. In a previous report of cyclosporine administered to a patient with atopic dermatitis and secondary FM, the course of FM was not described, but spiny follicular keratoses developed during cyclosporine administration, and all skin lesions cleared after cyclosporine was discontinued (5).5 Cyclosporine may be an effective option for the treatment of refractory FM, but it might cause adverse dermatological..."

IO biomarker • Journal • Alopecia • Atopic Dermatitis • Cutaneous T-cell Lymphoma • Dermatitis • Dermatology • Immunology • Mycosis Fungoides • Oncology • CD4 • CD8

PREVENTIVE EFFECT OF TOPICAL HYDROCORTISONE FOR CAPECITABINE-INDUCED HAND-FOOT SYNDROME IN COLORECTAL CANCER PATIENTS (T-CRACC STUDY) (MASCC-ISOO 2025) - "Methods Topical hydrocortisone butyrate 0.1% was applied prophylactically from the starting day of adjuvant chemotherapy with CAPOX (capecitabine 1000 mg/m2, day 1-14, and oxaliplatin 130 mg/m2, day 1, q3 weeks, for 8 cycles) after curative resection of colorectal cancer. Adverse events caused by topical hydrocortisone butyrate 0.1% was not observed. Conclusions Topical hydrocortisone butyrate 0.1% may prevent grade ≥2 HFS."

Clinical • Colorectal Cancer • Dermatology • Oncology • Solid Tumor

Clinical observation of Xuanyimeifu soothing milk in the treatment of mild atopic dermatitis (ChiCTR) - P=N/A | N=90 | Completed | Sponsor: Xuanwu Hospital Capital Medical University; Xuanwu Hospital Capital Medical University

New trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

A randomized controlled trial of platelet-rich plasma therapy for lichenoid vulvar disease (ChiCTR) - P=N/A | N=234 | Not yet recruiting | Sponsor: West China Second Hospital of Sichuan University; West China Second Hospital of Sichuan University

New trial

Randomized Controlled Trial of Physical Energy-Based Therapy for Lichenoid Vulvar Disease in Women (ChiCTR) - P1 | N=1184 | Not yet recruiting | Sponsor: West China Second Hospital of Sichuan University; West China Second Hospital of Sichuan University

New P1 trial

Material basis of toad oil and its pharmacodynamic effect in a mouse model of atopic dermatitis (PubMed, Zhongguo Zhong Yao Za Zhi) - "The modeled animals were respectively administrated with positive drug(0.1% hydrocortisone butyrate cream) and low-and high-doses(1%, 10%) of toad oil by gavage...This study comprehensively analyzes the chemical composition and clarifies the material basis of toad oil. Meanwhile, this study proves that toad oil has a good therapeutic effect on AD and is a reserve resource of traditional Chinese medicine for external use in the treatment of AD."

Journal • PK/PD data • Preclinical • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Topical application of Artemisia annua L. essential oil ameliorates 2,4-dintrochlorobenzene-induced atopic dermatitis in mice. (PubMed, J Ethnopharmacol) - "This study systematically demonstrated the possible therapeutic effects and mechanisms of AAEO in AD via network pharmacological analysis and experimental confirmation. These results revealed that topical application of AAEO can suppress skin inflammation and restore skin barrier function. These findings provide the potential application of AAEO in synthesizing external preparations for both pharmacological and cosmetic industries."

Journal • Preclinical • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation • FLG • IL10 • IL1B • IL6 • TNFA

Acute generalized exanthematous pustulosis caused by hydroxychloroquine in a patient with rheumatoid arthritis and CARD14 mutation: Case report. (PubMed, Medicine (Baltimore)) - "A 28-year-old woman with rheumatoid arthritis, treated with leflunomide therapy without marked relief of joint pain, developed multiple rashes with pruritis covering the body 5 days after switching to hydroxychloroquine treatment...The patient was treated using ketotifen fumarate tablets, dexamethasone sodium phosphate, calcium gluconate injection, methylprednisolone injection, vitamins C and B12, hydrocortisone butyrate cream, Reed acne cream, potassium chloride tablets, and pantoprazole enteric-coated capsules...There has been little basic research on AGEP-related genetics, and the CARD14 mutation may underlie several pustular rashes, including AGEP and generalized pustular psoriasis. Follow-up studies and further accumulation of patient data are required."

Journal • Acne Vulgaris • Dermatology • Immunology • Inflammatory Arthritis • Musculoskeletal Diseases • Musculoskeletal Pain • Orthopedics • Pain • Pruritus • Psoriasis • Pustular Psoriasis • Rheumatoid Arthritis • Rheumatology

Study protocol of a single-arm phase 2 study evaluating the preventive effect of topical hydrocortisone for capecitabine-induced hand-foot syndrome in colorectal cancer patients receiving adjuvant chemotherapy with capecitabine plus oxaliplatin (T-CRACC study). (PubMed, BMC Gastroenterol) - "This study is expected to contribute to the establishment of new supportive care for preventing HFS, not only for colorectal cancer patients receiving adjuvant chemotherapy, but also for various cancer patients receiving capecitabine-based chemotherapy."

Journal • P2 data • Colorectal Cancer • Dermatology • Gastrointestinal Cancer • Oncology • Solid Tumor

Fitting Pharmacodynamic Data to the E Model to Assess the Inherent Potency of Topical Corticosteroids. (PubMed, Mol Pharm) - "However, there was no significant difference between hydrocortisone butyrate and clobetasol propionate, while there was a significant difference between clobetasol propionate, fluticasone propionate, and mometasone furoate...Furthermore, the potencies of betamethasone valerate and methylprednisolone aceponate were similar but lower than those of all of the other APIs. The application of the VCA to classify inherent potency provides a reliable method to establish a classification system for TCs. Inherent potency assessment of TCs provides information that will be useful when choosing an appropriate TC for the development of a TCP for a specific clinical indication."

Journal • PK/PD data

Comparison of the Effect of Steroids on the Treatment of Phimosis according to the Steroid Potencies. (PubMed, Urol J) - "Topical steroid application is an effective and safe procedure as first-line treatment in symptomatic boys with severe phimosis. Moreover, the potency of topical steroids for the treatment of phimosis is considered a factor affecting the success rate."

Journal

Treatment of Tracheostomy Granulomas (clinicaltrials.gov) - P4; N=25; Completed; Sponsor: University of Colorado, Denver; Enrolling by invitation ➔ Completed

Trial completion

A Study of Crisaborole Ointment 2%; Crisaborole Vehicle; TCS and TCI in Subjects Aged ≥ 2 Years, With Mild-moderate AD (clinicaltrials.gov) - P3b/4; N=238; Terminated; Sponsor: Pfizer; N=178 ➔ 238; Trial completion date: Mar 2023 ➔ Dec 2020; Active, not recruiting ➔ Terminated; Trial primary completion date: Mar 2023 ➔ Dec 2020; This decision was made for business reasons only and is not related to any safety concerns regarding crisaborole.

Clinical • Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Pediatrics

A Study of Crisaborole Ointment 2%; Crisaborole Vehicle; TCS and TCI in Subjects Aged ≥ 2 Years, With Mild-moderate AD (clinicaltrials.gov) - P3b/4; N=178; Active, not recruiting; Sponsor: Pfizer; Recruiting ➔ Active, not recruiting; N=600 ➔ 178

Clinical • Enrollment change • Enrollment closed • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Pediatrics

Drugs for atopic dermatitis. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

A Study of Crisaborole Ointment 2%; Crisaborole Vehicle; TCS and TCI in Subjects Aged ≥ 2 Years, With Mild-moderate AD (clinicaltrials.gov) - P3b/4; N=600; Recruiting; Sponsor: Pfizer; Trial completion date: Mar 2021 ➔ Mar 2023; Trial primary completion date: Mar 2021 ➔ Mar 2023

Clinical • Trial completion date • Trial primary completion date • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Pediatrics

Treatment of Tracheostomy Granulomas (clinicaltrials.gov) - P=N/A; N=45; Enrolling by invitation; Sponsor: University of Colorado, Denver; N=30 -> 45 ; Trial primary completion date: Jan 2015 ->Jan 2016

Enrollment change • Trial primary completion date • Biosimilar

Treatment of Tracheostomy Granulomas (clinicaltrials.gov) - P=N/A; N=45; Enrolling by invitation; Sponsor: University of Colorado, Denver; Trial primary completion date: Jan 2016 ➔ Jan 2017

Trial primary completion date • Biosimilar

Valeant Pharmaceuticals to acquire Precision Dermatology for $475 million (Valeant Press Release) - "Valeant Pharmaceuticals...today announced that it has entered into a definitive agreement under which Valeant will acquire PreCision Dermatology, Inc. for $475 million in cash, plus an additional $25 million payable upon the achievement of a sales-based milestone....The transaction is expected to close in the first half of 2014..."

Anticipated M & A • Psoriasis

Vasoconstriction Trial With LEO 90100 Aerosol Foam (clinicaltrials.gov) - P1; N=36; Recruiting; Sponsor: LEO Pharma; Not yet recruiting ➔ Recruiting

Enrollment open • Biosimilar • Immunology • Psoriasis

Treatment of Tracheostomy Granulomas (clinicaltrials.gov) - P4; N=20; Enrolling by invitation; Sponsor: University of Colorado, Denver; Trial completion date: Jan 2018 ➔ Jan 2022; Trial primary completion date: Jan 2018 ➔ Jan 2022

Trial completion date • Trial primary completion date • Biosimilar

The diversity and evolution of pollination systems in large plant clades: Apocynaceae as a case study. (PubMed, Ann Bot) - "The less phenotypically specialized flowers of the Rauvolfioids are pollinated by a more restricted set of pollinators than are more complex flowers within the Apocynoids + Periplocoideae + Secamonoideae + Asclepiadoideae (APSA) clade...Variation in transition rates between pollination systems suggest constraints on their evolution, whereas regional differences point to environmental effects such as filtering of certain pollinators from habitats. This is the most extensive analysis of its type so far attempted and gives important insights into the diversity and evolution of pollination systems in large clades."

Clinical • Journal